Patents by Inventor Debasis Patnaik
Debasis Patnaik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11639325Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.Type: GrantFiled: December 9, 2020Date of Patent: May 2, 2023Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Li-Huei Tsai, Stephen J. Haggarty, Debasis Patnaik, Ping-Chieh Pao
-
Publication number: 20220064151Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.Type: ApplicationFiled: August 9, 2021Publication date: March 3, 2022Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
-
Patent number: 11180438Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.Type: GrantFiled: June 15, 2018Date of Patent: November 23, 2021Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Li-Huei Tsai, Stephen J. Haggarty, Debasis Patnaik, Ping-Chieh Pao
-
Patent number: 11084803Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.Type: GrantFiled: December 21, 2018Date of Patent: August 10, 2021Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
-
Publication number: 20210171429Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.Type: ApplicationFiled: December 9, 2020Publication date: June 10, 2021Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Li-Huei Tsai, Stephen J. Haggarty, Debasis Patnaik, Ping-Chieh Pao
-
Publication number: 20200087236Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.Type: ApplicationFiled: June 15, 2018Publication date: March 19, 2020Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Li-Huei TSAI, Stephen J. HAGGARTY, Debasis PATNAIK, Ping-Chieh PAO
-
Publication number: 20190211000Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.Type: ApplicationFiled: December 21, 2018Publication date: July 11, 2019Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
-
Patent number: 10167277Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.Type: GrantFiled: August 25, 2015Date of Patent: January 1, 2019Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
-
Publication number: 20180290960Abstract: The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.Type: ApplicationFiled: June 15, 2018Publication date: October 11, 2018Inventors: Li-Huei TSAI, Stephen HAGGARTY, Debasis PATNAIK, Ping-Chieh PAO
-
Publication number: 20160280693Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.Type: ApplicationFiled: August 25, 2015Publication date: September 29, 2016Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
-
Patent number: 9115053Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).Type: GrantFiled: July 20, 2012Date of Patent: August 25, 2015Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
-
Publication number: 20130231360Abstract: The present disclosure is directed to compounds of Formula (I) which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.Type: ApplicationFiled: April 21, 2011Publication date: September 5, 2013Applicant: THE BRIGHAM AND WOMEN S HOSPITAL, INC.Inventors: Jonathan Higgins, Debasis Patnaik, Natalia Ulyanova, Ross L. Stein, Jun Xian, Marcie Glicksman, Gregory D. Cuny
-
Publication number: 20130102627Abstract: The present disclosure is directed to compounds of Formula I: which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.Type: ApplicationFiled: April 8, 2011Publication date: April 25, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Jonathan Higgins, Gregory D. Cuny, Marcie Glicksman, Debasis Patnaik, Maxime Robin, Ross L. Stein, Jun Xian
-
Publication number: 20130096129Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).Type: ApplicationFiled: July 20, 2012Publication date: April 18, 2013Inventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
-
Patent number: 7470832Abstract: A highly efficient in-vitro system of micropropagation of rose scented Geranium, Pelargonium graveolens L. Herit by a direct regeneration method to produce a large number of viable true to the type plants maintaining the genotype of an elite mother plant is provided. The process involves inoculating nodal explants on shoot regeneration and multiplication medium, transferring the multiple shots for further growth on medium for shoot growth, further transferring the shoot with sufficient growth to medium for rooting. The present invention also provides a process for the primary and secondary hardening of the in vitro generated plants with the efficient root regeneration system, which is hardened to give about 95% survival in the field conditions. The multiplication ratio achieved by the process is of the order of 1:12-1:20, resulting in significantly low cost of production in relatively lesser time.Type: GrantFiled: June 3, 2003Date of Patent: December 30, 2008Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Anil Kush Kumar, Debasis Patnaik
-
Patent number: 7445932Abstract: Solanum viarum is an alkaloid producing plant of the family Solanaceae with varied therapeutic uses. In order to grow the plant in large areas; one needs to have an efficient system of vegetative multiplication, which ensures its genetic uniformity, and true to the type nature. In nature largely seeds propagate plant, which could be result of cross-pollination which may result in genetic drift. The present invention provides an efficient micropropagation system, with high level of multiplication at relatively low cost of production. The multiplication ratio was as high as 1:6 and almost 95% the plants were viable and successfully cultivated in field. The present invention provides an ideal way of mass cultivation of the selected elite plant material.Type: GrantFiled: June 3, 2003Date of Patent: November 4, 2008Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Anil Kush Kumar, Debasis Patnaik
-
Publication number: 20050076413Abstract: A highly efficient in-vitro system of micropropagation of rose scented Geranium, Pelargonium graveolens L. Herit by a direct regeneration method to produce a large number of viable true to the type plants maintaining the genotype of an elite mother plant is provided. The process involves inoculating nodal explants on shoot regeneration and multiplication medium, transferring the multiple shots for further growth on medium for shoot growth, further transferring the shoot with sufficient growth to medium for rooting. The present invention also provides a process for the primary and secondary hardening of the in vitro generated plants with the efficient root regeneration system, which is hardened to give about 95% survival in the field conditions.Type: ApplicationFiled: June 3, 2003Publication date: April 7, 2005Applicant: Reliance Life Sciences Pvt. Ltd.Inventors: Anil Kumar, Debasis Patnaik
-
Publication number: 20030226180Abstract: Solanum viarum is an alkaloid producing plant of the family Solanaceae with varied therapeutic uses. In order to grow the plant in large areas; one needs to have an efficient system of vegetative multiplication, which ensures its genetic uniformity, and true to the type nature. In nature largely seeds propagate plant, which could be result of cross-pollination which may result in genetic drift. The present invention provides an efficient micropropagation system, with high level of multiplication at relatively low cost of production. The multiplication ratio was as high as 1:6 and almost 95% the plants were viable and successfully cultivated in field. The present invention provides an ideal way of mass cultivation of the selected elite plant material.Type: ApplicationFiled: June 3, 2003Publication date: December 4, 2003Applicant: Reliance Life Sciences Pvt. Ltd.Inventors: Anil Kush Kumar, Debasis Patnaik